@article{fdi:010078453,
  title = {{W}hen the cure kills-{CBD} limits biodiversity research},
  author = {{D}ivakaran {P}rathapan, {K}. and {P}ethiyagoda, {R}. and {B}awa, {K}.{S}. and {R}aven, {P}.{H}. and {D}harma {R}ajan, {P}. and {G}aubert, {P}hilippe and et al.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}he {C}onvention on {B}iological {D}iversity ({CBD}) commits its 196 nation parties to conserve biological diversity, use its components sustainably, and share fairly and equitably the benefits from the utilization of genetic resources. {T}he last of these objectives was further codified in the {C}onvention's {N}agoya {P}rotocol ({NP}), which came into effect in 2014. {A}lthough these aspirations are laudable, the {NP} and resulting national ambitions on {A}ccess and {B}enefit {S}haring ({ABS}) of genetic resources have generated several national regulatory regimes fraught with unintended consequences (1). {A}nticipated benefits from the commercial use of genetic resources, especially those that might flow to local or indigenous communities because of regulated access to those resources, have largely been exaggerated and not yet realized. {I}nstead, national regulations created in anticipation of commercial benefits, particularly in many countries that are rich in biodiversity, have curtailed biodiversity research by in-country scientists as well as international collaboration (1). {T}his weakens the first and foremost objective of the {CBD}-conservation of biological diversity. {W}e suggest ways that the {C}onference of the {P}arties ({C}o{P}) of the {CBD} may proactively engage scientists to create a regulatory environment conducive to advancing biodiversity science.},
  keywords = {{MONDE}},
  booktitle = {},
  journal = {{S}cience},
  volume = {360},
  numero = {6396},
  pages = {1405--1406},
  ISSN = {0036-8075},
  year = {2018},
  DOI = {10.1126/science.aat9844},
  URL = {https://www.documentation.ird.fr/hor/fdi:010078453},
}